Sana Biotechnology files to go public, 2021 IPO: takeaways from S-1
Juno Therapeutics Sana Biotechnology is set to start trading on Thursday. The secretive Seattle-based biotech had raised $705.5 million since it was founded in July 2018. We dug through its 271-page filing to unearth five key details on the Sana's financials, strategy, and future. After raising more than $700 million since its 2018 launch, one of the biotech industry's most valuable private companies is set to start trading on Thursday. Seattle-based Sana Biotechnology filed paperwork on January 14 for an initial public offering. Following a red-hot year for bi...